Data

Mild non-invasive brain stimulation for apathy in Huntington's disease

Monash University

Dataset description

Randomized and counterbalanced sequence of three sessions of transcranial alternating current stimulation (tACS) conducted at least 72 hours apart, with details as follows:
1) 20 minutes and 2mA at the participants peak individualised alpha frequency;
2) 20 minutes and 2mA at 2Hz (delta frequency);
3) 20 minutes of sham (placebo) with 30 seconds 'fade in' followed by an immediate 30 seconds 'fade out'.
TACS is administered using a Startstim wireless hybrid electroencephalography(EEG)/transcranial current stimulation 8-channel system (Neuroelectrics, Spain).
EEG obtained via a 50-channel Neuroscan EEG system.
All data collection (baseline measures, resting and task-related EEG) and tACS administration is conducted by Marie-Claire Davis (Registered Psychologist with practice endorsement in Clinical Neuropsychology and PhD candidate).
Click to explore relationships graph

Source Study

Trial acronym

Not available

Trial ID

ACTRN12619000870156

Purpose

Treatment

Phase

Not Applicable

Funding

University,Monash University

Scientific enquiries

Prof Kate Hoy

Brief Summary

Many people with Huntington’s disease (HD) experience problems with motivation, often referred to as “apathy”. This is thought to be because of how HD affects the frontal lobes of the brain. There are currently no effective treatments for apathy in HD. Recent research has looked at whether non-invasive brain stimulation can improve motivation in people experiencing other neurological conditions (e.g., stroke) with some promising results. The type of brain changes caused by HD mean that a gentle, ....
Read more

Key Inclusion Criteria

- Individuals with genetically confirmed prodromal or early stage HD, as well as individuals without HD matched for age, gender and education will be sought as participants. - Participants with prodromal HD will need to be within approximately 12 years of expected motor onset or have a “disease burden score” (DBS) of at least 280, indices calculated using the prospective participant’s current age and number of CAG repeats on the affected allele. - Participants with early stage manifest HD will n ....
Read more

Key Exclusion Criteria

- Use of anticonvulsant medications or regular treatment with benzodiazepines (versus limited as-needed use, with none consumed within the 48 hours prior to an experimental session). - Commencement or significant dosage alteration of other psychotropic medications (i.e., anti-depressants, anti-psychotics) during the four weeks prior to an experimental session. - Choreiform movements that preclude tACS or EEG data collection. - A current episode of psychiatric illness, or a current substance use ....
Read more

Can healthy volunteers participate?

Yes

 

Population

Sample Size    44

Min. age    18 Years

Max. age    75 Years

Sex    Both males and females

Condition category    Apathy , Huntington's disease

Condition code    Human Genetics and Inherited Disorders , Neurological

Intervention

Intervention code Treatment: Devices

Randomized and counterbalanced sequence of three sessions of transcranial alternating current stimulation (tACS) conducted at least 72 hours apart, with details as follows: 1) 20 minutes and 2mA at the participants peak individualised alpha frequency; 2) 20 minutes and 2mA at 2Hz (delta frequency); 3) 20 minutes of sham (placebo) with 30 seconds 'fade in' followed by an immediate 30 seconds 'fade out'. TACS is administered using a Startstim wireless hybrid electroencephalography(EEG)/transcrania ....
Read more

Comparison

Control group Placebo

3) 20 minutes of sham (placebo) with 30 seconds 'fade in' followed by an immediate 30 seconds 'fade out'.

Outcomes

Outcome: Changes in resting power on electroencephalogram (EEG).
Timepoint: Resting eyes closed and eyes open EEG measured immediately before and immediately after each stimulation condition.

Outcome: Changes in event-related EEG activity during completion of the Monetary Incentive Delay (MID) task.
Timepoint: The MID task completed immediately before and immediately after each stimulation condition.

Study Protocol: Not Available
Data Dictionary: Not Available

Will individual participant data (IPD) for this trial be available?

yes

What data in particular will be shared?

Individual participant de-identified data.

When will data be available?

If and when required as part of publishing the results. Outside these circumstances, then January 2023.

Available to whom?

Researchers who agree to preserve the confidentiality of the data, provide information regarding the proposed use of the data, and pending approval from the original research team.

Available for what types of analyses?

As approved by the original research team.

Source study information is derived from the Australian New Zealand Clinical Trials Registry (ANZCTR). For more information on the ANZCTR, please see anzctr.org.au